217 completed, 72 unknown, 38 terminated, 18 recruiting. 246 Phase 2, 82 Phase 3, 30 Phase 1, 18 Phase 4, 16 Not applicable.
Follow Thalidomide: new trials by email Literature Review of Thalidomide trials Research Report on Thalidomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-Thalassemia Thalidomide, Danazol, Prednisolone - Beta-Thalassemia, Thalassemia | Phase 3 | Recruiting | Khyber Medical University Peshawar | 172 | 2026-10-12 | 2026-10-21 |
| Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction Dovramilast, Prednisolone, Thalidomide - Erythema Nodosum Leprosum | Phase 2 | Recruiting | Medicines Development for Global Health | 45 | 2026-09-15 | 2026-10-06 |
| The Efficacy of CAPCT in Patients With PTCL Chidamide, Azacitidine (AZA), Prednisone - Peripheral T-Cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 58 | 2026-08-01 | 2026-08-05 |
| Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia Thalidomide, Hydroxy Urea - Thalassemia | Not applicable | Recruiting | Riphah International University | 240 | 2026-06-20 | 2026-08-06 |
| Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors Gemcitabine, Mitomycin C, Thalidomide - Solid Tumor Cancer | Phase 2 | Recruiting | Sarcoma Oncology Research Center, LLC | 60 | 2026-06-01 | 2026-06-26 |
| Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome Thalidomide (50mg), Colchicine - Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis Syndrome | Not applicable | Not yet recruiting | Wenjie Zheng | 106 | 2026-04-01 | 2026-03-17 |
| Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients Luspatercept combined with low-dose thalidomide, Luspatercept plus placebo - Transfusion-dependent β-thalassemia Patients | Phase 2 | Recruiting | Rongrong Liu | 78 | 2026-02-01 | 2026-01-13 |
| A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma Apatinib, Camrelizumab, TACE - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Zhongshan Hospital | 222 | 2025-12-22 | 2025-12-30 |
| Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH Selinexor, Thalidomide (100mg), Dexamethasone - Langerhans Cell Histiocytosis (LCH) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2025-08-01 | 2025-10-02 |
| Bevacizumab in the Treatment of HHT Bevacizumab, nasal electrocoagulation., Thalidomide (50mg) - Bevacizimab, HHT | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2025-05-01 | 2026-09-18 |
| Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH Cytarabine (Ara-C), Thalidomide (100mg) - Langerhans Cell Histiocytosis | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 50 | 2025-04-12 | 2025-09-22 |
| Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease anti-BCMA/GPRC5D bispecific CAR-T, Apornemin, Carfilzomib - Extramedullary Multiple Myeloma | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-04-09 | 2025-08-14 |
| Thalidomide Versus Argon Plasma Coagulation in Gastric Antral Vascular Ectasia(GAVE)-Related Anaemia in Cirrhosis (TAG Trial) Thalidomide, Argon Plasma Coagulation - Liver Cirrhosis, Gastric Antral Vascular Ectasia | Not applicable | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 100 | 2025-01-05 | 2025-01-13 |
| Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury. Thalidomide, Glutamine, Thalidomide+Glutamine - Radiation Enteritis | Phase 2 | Recruiting | Yongquan Shi | 150 | 2024-09-30 | 2026-03-27 |
| Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia Thalidomide and methotrexate - T-LGL Leukemia, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 48 | 2024-08-10 | 2025-11-18 |
| Thalidomide Therapy for VEOIBD Thalidomide - Inflammatory Bowel Diseases | Recruiting | Children's Hospital of Fudan University | 40 | 2024-05-15 | 2025-05-22 | |
| Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia Thalidomide - Fetal Hemoglobin, Thalassemia Major | Phase 2 | Recruiting | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 54 | 2024-04-22 | 2025-05-30 |
| 3T Therapy in the Treatment of MDA5-positive Dermatomyositis Tofacitinib 5 MG - Dermatomyositis | Phase 4 | Enrolling by invitation | Second Affiliated Hospital, Zhejiang University, School of Medicine | 133 | 2024-03-19 | 2024-06-03 |
| The Therapeutic Effect of Thalidomide in Syringomyelia Thalidomide - Syringomyelia, Thalidomide | Phase 2 | Recruiting | Xuanwu Hospital, Beijing | 30 | 2024-02-01 | 2024-02-20 |
| Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) Camrelizumab, Thalidomide 50mg, Thalidomide 100mg - Lung Cancer, Nonsmall Cell, Esophageal Carcinoma | Phase 2 | Unknown | Henan Cancer Hospital | 132 | 2024-01-19 | 2024-03-29 |
Showing 20 of 372. Sign in to see all of them.
Multiple Myeloma (121) · Neoplasms, Plasma Cell (36) · Neoplasms (14) · Carcinoma, Hepatocellular (13) · Recurrence (13) · Brain Neoplasms (12) · Central Nervous System Neoplasms (11) · HIV Infections (11) · Melanoma (11) · Prostatic Neoplasms (11) · Glioblastoma (10) · Carcinoma, Non-Small-Cell Lung (9) · Leukemia (9) · Thalassemia (9) · Acquired Immunodeficiency Syndrome (8)
National Cancer Institute (NCI) (29) · University of Arkansas (24) · M.D. Anderson Cancer Center (11) · Memorial Sloan Kettering Cancer Center (9) · Dana-Farber Cancer Institute (8) · SWOG Cancer Research Network (8) · Institute of Hematology & Blood Diseases Hospital, China (6) · Roswell Park Cancer Institute (5) · Weill Medical College of Cornell University (5) · Case Comprehensive Cancer Center (4) · Celgene (4) · Celgene Corporation (4) · Mayo Clinic (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Wake Forest University Health Sciences (4)
United States (197) · China (61) · Italy (19) · France (16) · United Kingdom (15) · Pakistan (11) · South Korea (11) · Germany (10) · Spain (10) · Austria (8) · Taiwan (8) · Belgium (6) · Australia (5) · Brazil (5) · Canada (5)
Mohamad A. Hussein, MD (4) · Athanasios Fassas, M.D. (3) · Bart Barlogie, MD, PhD (3) · Mark W. Kieran, MD, PhD (3) · A. Keith Stewart, MD (2) · Barthel Barlogie, M.D., Ph.D. (2) · D. McMeekin (2) · Gordan Srkalovic, MD, PhD (2) · Heinz Ludwig, MD (2) · Jinglin Xia, MD (2) · Kelvin Lee, MD (2) · Laura F. Hutchins, MD (2) · Mario Boccadoro, MD (2) · Maurizio Zangari, MD (2)
PMID 22689675, PMID 33357481, PMID 40501401, PMID 29567784, PMID 22674807, PMID 21106711, PMID 21160068, PMID 21228328, PMID 23305732, PMID 23603914, PMID 23897961, PMID 24281461, PMID 27581518, PMID 29931453, PMID 35477175, PMID 36188432, PMID 38023148, PMID 40471585, PMID 10893291, PMID 11419162, PMID 11788559, PMID 12039921, PMID 12947072, PMID 15016759, PMID 15057291, PMID 15623591, PMID 15867202, PMID 15967833, PMID 16051743, PMID 16224404, PMID 16249352, PMID 16282886, PMID 16365178, PMID 16398649, PMID 16495695, PMID 16525139, PMID 16530576, PMID 16905712, PMID 17031561, PMID 17254484, PMID 17406356, PMID 17620452, PMID 17920916, PMID 17932881, PMID 18031363, PMID 18166796, PMID 18213528, PMID 18362366, PMID 18403492, PMID 18425621
U10CA032102 (7), 2005 (4), P30CA006516 (4), P30CA043703 (4), U10CA021115 (4), U10CA027469 (4), P30CA008748 (3), U10CA025224 (3), 2016 (2), M01RR000096 (2), P30CA015083 (2), P30CA022453 (2), P30CA033572 (2), U10CA021661 (2), U10CA031946 (2)